Status:
UNKNOWN
Induced Angiogenesis by Genic Therapy in Advanced Ischemic Cardiomyopathy
Lead Sponsor:
Instituto de Cardiologia do Rio Grande do Sul
Collaborating Sponsors:
Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Conditions:
Ischemic Cardiopathy
Eligibility:
All Genders
Up to 75 years
Phase:
PHASE2
Brief Summary
Human Vascular Endothelial Grown Factor 165 (hVEGF165) administration is promising therapy induces a new vessels, arterioles and capillaries in regions whose revascularization surgery is not possible ...
Eligibility Criteria
Inclusion
- Diagnosis coronary artery disease and symptomatic, despite optimal pharmacologic therapy
- Left ventricular dysfunction - left ventricular ejection fraction between 60% and 25% by echocardiogram
- Non-conventional revascularization, as seen by cineangiocardiography, attested by interventional cardiologist and cardiac surgeon
- Age below 75 years
- Absence of neoplasm
Exclusion
- No
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2009
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00744315
Start Date
November 1 2007
End Date
May 1 2009
Last Update
October 15 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Cardiology of Rio Grande do Sul / FUC
Porto Alegre, Rio Grande do Sul, Brazil, 90620001